While Aß immunotherapy presently represents the most promising approach for the treatment of AD, one adverse effect is the occurrence of microhemorrhages as described in APP transgenic mice following passive [16, 77] or active Aß immunization [16], including that seen with AN1792 during clinical trials [21, 78]. Here, APP is linked to Alzheimer disease.